EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies

Francesco Maria Animati iD, Simone Proietti, Francesco Auletta, Rocco Antonio Montone iD, Luigi Cappannoli iD, Francesco Fracassi iD, Achille Gaspardone, Francesco Burzotta

Journal of Clinical Medicine · 28.07.2026 · 15 (15) · 5897

DOI: 10.3390/jcm15155897 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 28.07.2026. Verfasst von Francesco Maria Animati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Cardiovascolari e Pneumologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy. Die Arbeit nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipoprotein(a) (Lp(a)) is increasingly recognized as a genetically determined and clinically relevant contributor to residual cardiovascular risk. Through pro-atherogenic, pro-inflammatory, pro-thrombotic, and pro-calcific mechanisms, Lp(a) appears to play a significant role in both coronary artery disease and aortic valve disease. In patients undergoing percutaneous coronary intervention, elevated Lp(a) has been associated with worse long-term outcomes, including recurrent ischemic events, repeat revascularization, and in-stent restenosis, even in the setting of controlled low-density lipoprotein cholesterol. In parallel, experimental, genetic, and clinical data support a role for Lp(a) in the initiation and progression of calcific aortic stenosis, while its prognostic significance after transcatheter aortic valve interventions remains less clearly defined. Current guidelines now recognize Lp(a) as a relevant risk-enhancing factor, and emerging targeted therapies are achieving substantial reductions in circulating levels. Overall, Lp(a) should be regarded as both a meaningful biomarker and a promising therapeutic target, although ongoing outcome trials are needed to determine whether selective Lp(a) lowering translates into clinical benefit across interventional cardiovascular settings. The aim of this narrative review is to provide a single, comprehensive account of lipoprotein(a) [Lp(a)] in interventional cardiology, following this lipoprotein from its biology and pathophysiology through to its clinical impact and to the therapies that are now reaching the clinic, with a specific focus on the two most frequent catheter-based procedures in which it may carry prognostic weight: percutaneous coronary intervention (PCI) and transcatheter aortic valve implantation (TAVI). PCI and TAVI are deliberately addressed within the same review since they share a common upstream biology: Lp(a) contributes both to the atherosclerotic process that underlies coronary disease and to the calcific process that underlies aortic valve disease, and the corresponding patient populations overlap considerably in everyday interventional practice. Covering them together offers the interventional cardiologist a single, practical reference on how a patient with elevated Lp(a) may be approached in both scenarios.

Schlagwörter

Stichwörter der Autor:innen

coronary inflammationlipoprotein(a)percutaneous coronary interventionresidual risktranscatheter aortic valve implantation

Autor:innen und Institutionen

  • Dipartimento di Scienze Cardiovascolari e Pneumologiche, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Department of Cardiovascular Medicine-CUORE, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
  • Division of Cardiology, Sant'Eugenio Hospital, 00144 Rome, Italy.

ORCID-Profile: Francesco Maria Animati, Rocco Antonio Montone, Luigi Cappannoli, Francesco Fracassi

Zitieren

APA

Animati, F. M., Proietti, S., Auletta, F., Montone, R. A., Cappannoli, L., Fracassi, F., Gaspardone, A., & Burzotta, F. (2026). Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies. Journal of Clinical Medicine, 15(15), 5897. https://doi.org/10.3390/jcm15155897

Vancouver

Animati FM, Proietti S, Auletta F, Montone RA, Cappannoli L, Fracassi F, et al. Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies. Journal of Clinical Medicine. 2026;15(15):5897. doi:10.3390/jcm15155897

BibTeX
@article{Animati2026,
  author = {Animati, Francesco Maria and Proietti, Simone and Auletta, Francesco and Montone, Rocco Antonio and Cappannoli, Luigi and Fracassi, Francesco and Gaspardone, Achille and Burzotta, Francesco},
  title = {Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {15},
  pages = {5897},
  doi = {10.3390/jcm15155897}
}
Kostenlos starten →